ADC Therapeutics is categorized as a specialized, commercial-stage global biotechnology enterprise operating with a focused workforce of approximately 200 to 260 professional employees distributed across its primary research and development headquarters in Lausanne, Switzerland, and its operational branch in New Jersey, United States. The company commands a micro-to-small-cap market valuation on public exchanges while maintaining active collaborations with major global oncology networks and clinical trial centers.